Novo Nordisk CEO signals possible US listing upgrade to attract investors

Novo Nordisk's CEO Mike Doustdar indicated openness to upgrading the company's US listing, citing advantages of direct access for US investors. This marks a potential strategic shift in capital markets positioning, though no formal decision has been made. The move could enhance liquidity and valuation, reflecting broader trends of European firms seeking US listings.